Media
Library

This Blood Test May Detect Alzheimer’s Decades Before Symptoms

August 7, 2026

Click here to read AltPep’s LinkedIn post

Exciting podcast featuring Valerie Daggett, AltPep’s CEO and Founder, on The Bio Report

January 6, 2026

Listen to a highly informative discussion on the discovery of α-sheet toxic oligomers and their relationship to the onset of Alzheimer’s disease, how AltPep’s synthetic peptides are designed to detect and neutralize these pathogenic agents, and the potential for extending this platform to a broader set of amyloid diseases.

Click here for The Bio Report podcast rb.gy/enjvzn

Click here for a Q&A of the podcast

Revolutionary: The Quest to Detect and Cure Alzheimer’s

April 1, 2024

Early Detection, and Treatment, for Alzheimer's: Valerie Daggett on the Long Run

March 6, 2024

Would you like to hear more about how AltPep is recasting the amyloid hypothesis in Alzheimer’s disease? By focusing on the toxic oligomers present earlier in the process, AltPep aims to detect and treat AD before symptoms develop. Find out more about the vision and work of this exciting company from Valerie Daggett, founder and CEO by listening to The LongRun biotech podcast with Luke Timmerman.

Thank you Luke Timmerman for your time and interest in sharing AltPep’s groundbreaking story.

Click Here for the Full Article and Link to Soundcloud

From Discover to Design: Toward Early Detection and Treatment of Alzheimer’s Disease

October 13, 2022

Innovation Journeys: Stories of Invention & Discovery at UW: AltPep

October 13, 2021

Join UW Vice Provost for Innovation & CoMotion Director François Baneyx as he speaks with Dr. Valerie Daggett, Founder & CEO of UW spinoff AltPep (https://www.altpep.com/) and professor of bioengineering at the University of Washington, about her commercialization journey and how CoMotion supported it through funding, resources, programs and more.

The Risk of AIRA

Amyloid plaque are targeted and mobilized by anti-amyloid antibodies (such as lecanamab and donanamab). The antibody-bound plaque clear through the brain’s immune cells, called microglia, by binding Fc-gamma Receptors (FCgRs). (Alzheimers Dis Rep. 2023) This binding alters the microglia resulting in inflammation and cytokine storm and thereby creating a high risk of ARIA (https://ajronline.org/doi/epdf/10.2214/AJR.22.28461).

Linkedin-in

Valerie Daggett, PhD

Chief Executive Officer

Valerie, the CEO/Founder of AltPep and an Endowed Professor of Bioengineering at the University of Washington, has been a champion of groundbreaking research for over 30 years. Her inherent curiosity pushes her to uncover new ways of tackling problems in the field of amyloid diseases, where successes are few.  Her tenacity led to a revolutionary discovery of a protein structure that could dramatically change the diagnosis and treatment of Alzheimer’s disease and over 50 other amyloid diseases. At AltPep, Valerie leads a team of innovators who are developing this platform to make the early, pre-symptomatic diagnosis and treatment of amyloid diseases a reality. Valerie holds a BA from Reed College, PhD from the University of California, San Francisco, and was a Postdoctoral Fellow at Stanford University.